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Huntington’s disease (HD) is an incurable neurode-
generative disease caused by neuronal accumula-
tion of the mutant protein huntingtin. Improving
clearance of the mutant protein is expected to
prevent cellular dysfunction and neurodegeneration
in HD. We report here that such clearance can be
achieved by posttranslational modification of the
mutant Huntingtin (Htt) by acetylation at lysine
residue 444 (K444). Increased acetylation at K444
facilitates trafficking of mutant Htt into autophago-
somes, significantly improves clearance of the
mutant protein by macroautophagy, and reverses
the toxic effects of mutant huntingtin in primary
striatal and cortical neurons and in a transgenic
C. elegans model of HD. In contrast, mutant Htt that
is rendered resistant to acetylation dramatically accu-
mulates and leads to neurodegeneration in cultured
neurons and in mouse brain. These studies identify
acetylation as a mechanism for removing accumu-
lated protein in HD, and more broadly for actively
targeting proteins for degradation by autophagy.
INTRODUCTION
Accumulation and aggregation of mutant proteins is a hallmark
of several neurodegenerative disorders such as Parkinson’s,
Alzheimer’s, and Huntington’s disease (HD) (Ross and Poirier,
2004). One of the major therapeutic challenges in the field of neu-
rodegeneration has been to improve the degradation of accumu-
lated mutant proteins. While the ubiquitin-proteosome system
(UPS) represents an important defense against abnormal protein
accumulation, aggregation-prone proteins appear to be poor60 Cell 137, 60–72, April 3, 2009 ª2009 Elsevier Inc.substrates for proteosomal degradation and better targets for
autophagic-lysosomal degradation (Levine and Kroemer,
2008). In terms of the mode of cargo delivery to the lysosome,
three forms of autophagic degradation have been described
so far—microautophagy, chaperone-mediated autophagy, and
macroautophagy (Klionsky, 2007). This latter form, whereby
cytosolic constituents and organelles are engulfed by multila-
mellar vesicles which then fuse to the lysosome, has been impli-
cated in a wide array of neurological disorders including HD
(Cuervo, 2004; Nixon, 2005; Levine and Kroemer, 2008).
Huntington’s disease is a devastating neurodegenerative
disorder characterized by progressive and severe motor and
cognitive impairment; death ensues about 15 years after the
onset of symptoms (Vonsattel and DiFiglia, 1998). The mutation
is inherited as autosomal dominant and causes expansion of
a stretch of glutamines near the N terminus of huntingtin,
a protein of uncertain function whose mutant form accumulates
as nuclear and cytoplasmic inclusions in HD brain (DiFiglia et al.,
1997). In a conditional mouse model of HD, it was found that
elimination of mutant Huntingtin (Htt) expression not only halted
symptomatic progression but also led to regression of the
disease-like symptoms (Yamamoto et al., 2000). Initial experi-
ments in human HD brain found aberrant accumulation of hun-
tingtin in late endosomal structures, suggesting dependence
on autophagy (Sapp et al., 1997). Recent findings showed that
activation of autophagy by systemic administration of rapamycin
may be sufficient to partially ameliorate symptoms in an HD
mouse model (Ravikumar et al., 2004). While these and other
studies demonstrate neuroprotection by the inhibition of the
ubiquitous protein kinase mTOR and nonspecific activation of
autophagy, it remains unclear whether autophagy can be selec-
tively activated in order to remove disease proteins of interest.
In this study, we demonstrate a link between acetylation of
a nonhistone protein and targeted degradation by autophagy.
Modification of mutant huntingtin by acetylation promotes its tar-
geting into autophagosomes and facilitates specific degradation
of the mutant protein by the autophagic-lysosomal pathway.
Furthermore, we show that acetylation and clearance of mutant
huntingtin leads to neuroprotection in primary neurons and
a transgenicC. elegansmodel of HD, highlighting the importance
of selective targeting of disease proteins to autophagosomes for
degradation.
RESULTS
Mutant Huntingtin Is Acetylated at Lysine 444
Recent studies demonstrate that mutant Htt interacts directly
with the histone acetyltransferase (HAT) domain of CREB-
binding protein (CBP) (Steffan et al., 2001), suggesting possible
mutant Htt acetylation by CBP. To determine whether Htt gets
acetylated, COS-7 cells were transiently transfected with mutant
Htt containing the N-terminal 480 amino acids and 68 glutamines
(Htt480-68Q), treated with a combination of HDAC inhibitors tri-
chostatin A (TSA) and nicotinamide (NAM), and subjected to
tandem mass spectrometry (MS). Using three different mass
spectrometers at separate facilities, we repeatedly identified
a single acetyl-lysine-containing peptide (GKAcVLLGEEEA
LEDDSESR) mapping the acetylated lysine (K) to position 444
of human Htt (K444; Figure 1A). Protein sequence alignment of
Htt homologs from different species demonstrated conservation
of human K444 residue in mouse, rat, zebrafish, and pufferfish
(Figure S1A available online). Interestingly, K444 was identified
within the caspase 6 fragment of mutant Htt (586aa) that repre-
sents the required cleavage step for neurodegeneration due to
mutant Htt (Graham et al., 2006a).
In order to further characterize acetylation of Htt at K444,
a specific antibody against acetylated K444 (AcK444) was
generated. Using a dot blot assay, we demonstrated that the
antibody specifically reacted to K444-acetylated peptide but
not to the native peptide (Figure S1B). To further assess the
specificity of the antibody, lysine 444 was mutated to arginine
(R) in an expression vector encoding the N-terminal domain of
Htt with 97 glutamines (Htt590-97Q), generating an Htt590-
97Q-KR mutant construct. When overexpressed in COS-7 cells
in the presence of HDAC inhibitors, Htt590-97Q was detected
by the AcK444 antibody, but the K444R mutation completely
abrogated reactivity of AcK444 to Htt, demonstrating specificity
of AcK444 antibody for acetylated K444 (Figure 1B).
Next, we sought to identify the histone acetyltransferase (HAT)
and deacetylase (HDAC) responsible for acetylation/deacetyla-
tion of Htt at K444. A number of known HATs and HDACs were
examined by cotransfection together with mutant Htt (Htt480-
68Q). While p300, P/CAF, Tip60, HAT1, or HBO1 and a number
of HDACs did not alter Htt acetylation, CBP and HDAC1 strongly
increased and decreased the acetylation of mutant Htt, respec-
tively (Figures 1C and 1E). Consistent with a previous finding that
the glutamine-rich domain of CBP (CBPDQ) is not required for
the CBP/Htt interaction (Steffan et al., 2001), CBPDQ also effi-
ciently acetylated mutant Htt (Figure 1C). To determine if the
HAT domain of CBP was sufficient for Htt acetylation, CBP-HAT
was subcloned into a mammalian expression vector (Figure S2).
While CBP-HAT potently induced acetylation of Htt, mutagen-
esis of conserved aspartic acid residue (D1435) to tyrosine (Y)
in the HAT catalytic domain (CBP-HAT-DY) that eliminates HATactivity of CBP completely abolished the ability of CBP-HAT to
acetylate Htt at K444 (Figure 1D). Together, these findings
demonstrate the requirement of the functional HAT domain in
CBP for acetylation of Htt and suggest that a specific subset of
HATs and HDACs modulates Htt acetylation.
Mutant Huntingtin Is Acetylated at Lys444
in Heterozygous Mouse and Human HD Brain
Using the specific AcK444 antibody we next examined the acet-
ylation status of a 480 aa fragment of wild-type huntingtin
(Htt480-17Q) and mutant huntingtin (Htt480-68Q) in Neuro2a
cells. As shown in Figure 1F, treatment with HDAC inhibitors
primarily augmented the acetylation of mutant huntingtin while
acetylation of wild-type huntingtin was barely detectable despite
higher levels of the wild-type protein expression.
In order to examine acetylation of endogenous huntingtin in
the absence of overexpression, we tested brain samples from
wild-type, homozygous, or heterozygous knock-in mouse
models of HD that carry 111Q or 140Q polyglutamine stretches
knocked into the murine HD gene homolog (Menalled et al.,
2003; Wheeler et al., 1999). Surprisingly, probing with the
AcK444 antibody revealed that only mutant Htt was acetylated
in both the 140Q HD mouse brain (Figure 1G) and the 111Q
HD mouse brain (Figure 1H). Similarly, in heterozygous human
HD brain samples, only acetylation of the mutant but not the
wild-type form of Htt protein was detected in early or advanced
stages of disease (Figures 1I and S3A). These in vivo results were
consistent with the preferential acetylation of mutant Htt
observed in cultured cells (Figure 1F).
To examine, as a proof-of-principle, whether Htt acetylation
can be increased in mouse brains, heterozygous knock-in HD
mice (HdH7Q/140Q) were treated with a combination of TSA and
NAM for 10 days. Consistent with the results in cultured cells
(Figure 1F), we found that HDAC inhibitors increased acetylation
of the mutant but not the wild-type form of Htt (Figure S3B). Since
only the mutant protein was acetylated, we used the ratio of
mutant Htt over wild-type Htt to determine the effects of acety-
lation on total huntingtin protein levels. This approach revealed
a decrease in mutant but not the wild-type Htt levels in treated
animals (Figure S3B), suggesting that preferential acetylation of
mutant Htt in vivo may affect the stability of the mutant protein.
Acetylation-Resistant Mutant Htt Accumulates
in Cultured Neurons and in Mouse Brain
In order to examine if acetylation of K444 affects the stability of
mutant Htt in neurons, a lentiviral-mediated delivery of mutant
huntingtin was employed (Re´gulier et al., 2003). Analysis of
various lentiviral promoters revealed that the mouse phospho-
glycerate kinase (PGK) promoter resulted in easily detectable
expression of Htt in more than 90% of neurons at nontoxic titers
(Figure 2A, inset). Primary neuronal cultures were transduced
with acetylated (lenti-Htt571-72Q) or acetylation-resistant Htt
(lenti-Htt571-72Q-KR) and the expression monitored over
a period of 24 days. These experiments revealed significant
accumulation of lenti-Htt571-72Q-KR compared to lenti-
Htt571-72Q (Figure 2A), suggesting increased stability and
impaired clearance of acetylation-resistant mutant Htt. In order
to validate these observations in vivo, brains of wild-type miceCell 137, 60–72, April 3, 2009 ª2009 Elsevier Inc. 61
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Figure 1. Mutant Huntingtin Is Acetylated at Lysine 444
(A) LC-MS/MS spectrum of acetylated peptide GKAcVLLGEEEALEDDSESR obtained from Htt480-68Q. The unfragmented peptide as well as a series of b-ions
displayed a mass change of +42 Da, indicative of acetylation.
(B) Specificity of the Ac-K444 antibody was determined in COS-7 cells transfected with Htt590-97Q or Htt590-97Q-KR, treated with TSA and NAM, and analyzed
by western blotting.
(C) Htt480-68Q was transfected into COS-7 cells together with indicated HATs. Levels of total and acetylated Htt are shown. b-tubulin was used as loading control.
(D) CBP-HAT increases acetylation of Htt. COS-7 cells were transfected with Htt480-68Q and CBP-HAT domain, or HAT-deficient CBP-HAT-DY and Htt detected
with MAB5490 and AcK444 antibodies. CBP-HAT levels were analyzed by HA antibody.
(E) Htt is deacetylated by HDAC1. Neuro2a cells were transfected with Htt480-68Q along with CBP-HAT, vector, or HDACs 1–5 and levels of total and acetyl-Htt
determined by western blotting. b-tubulin was used as loading control. Equal expression of all HAT and HDAC constructs was confirmed by western blotting (not
shown). All data are representative of at least three independent experiments.
(F) Treatment with HDAC inhibitors increased acetylation of Htt at K444. Neuro2a cells were transfected with Htt480-17Q or Htt480-68Q and treated with TSA and
NAM. Htt was immunoprecipitated with anti-Htt antibody (MAB5490) and probed with AcK444 and MAB5490 antibodies. All data are representative of at least
three independent experiments.
(G) Full-length mutant Htt is acetylated in knock-in mouse brains. Brain samples of 140Q knock-in mice were analyzed with Htt antibody (MAB 5490; upper panel)
and acetyl-Htt antibody (lower panel). Comparison of wild-type (HdhQ7/Q7), heterozygous (HdhQ7/Q140), and homozygous (HdhQ140/Q140) animals revealed acety-
lation of only full-length mutant Htt (lower panel). At least three independent samples were examined and a representative blot is presented.
(H) Homogenates from 111Q knock-in mouse model were analyzed as in (G). The comparison of wild-type (HdhQ7/Q7) and heterozygous (HdhQ7/Q111) littermates
confirmed that only mutant Htt is acetylated in vivo (lower panels).
(I) Mutant huntingtin is acetylated in postmortem human HD brain. Htt was immunoprecipitated from postmortem brain tissues of presymptomatic heterozygous
HD subjects (grades 0–1) and advanced HD subjects (grades 3–4) (Figure S3A) and analyzed as in (G). The upper band representing mutant huntingtin was acet-
ylated at K444.were stereotaxically injected with lentiviral vectors expressing
lenti-Htt571-72Q or lenti-Htt571-72Q-KR. While no significant
accumulation was noted 4 weeks after injection, a dramatic
accumulation of lenti-Htt571-72Q-KR compared to lenti-62 Cell 137, 60–72, April 3, 2009 ª2009 Elsevier Inc.Htt571-72Q was observed 13 weeks after the injection
(Figure 2B). The accumulation of lenti-Htt571-72Q-KR led to
increased neurodegeneration as determined by a significant
decrease in the mean neuronal volumes of infected neurons
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Figure 2. Acetylation-Resistant Mutant Htt Accumulates in Cultured Neurons and in Mouse Brains
(A) Rat primary cortical neurons were transduced with acetylated (lenti-Htt571-72Q) or acetylation-resistant mutant Htt (lenti-Htt571-72Q-KR) on DIV2. More than
90% of neurons expressed lenti-Htt (Ab1 antibody) (inset). Twenty-four days post-infection lenti-Htt571-72Q-KR significantly accumulated compared to lenti-
Htt571-72Q. *p < 0.01 for three independent experiments.
(B) Lentiviral delivery of mutant Htt in mouse cortex and striatum. Expression of lenti-Htt571-72Q and lenti-Htt571-72Q-KR Htt in contralateral brain sections was
examined at 4 and 13 weeks after injection by immunostaining with EM48 antibody against mutant Htt. Serial sections from at least ten mice in each group were
examined. Representative sections show predominantly cytoplasmic neuronal expression of lenti-Htt571-72Q and cytoplasmic and nuclear expression of lenti-
Htt571-72Q-KR. Magnification 403 and 1003.
(C) Neuronal volumes were significantly decreased in lenti-Htt571-72Q-KR compared to lenti-Htt571-72Q injected mice. Unbiased stereological analysis (Micro-
BrightField) was performed 13 weeks after injection. Graphs represent means ± standard error of the mean (SEM) of five animals per group; *p < 0.01 compared to
72Q.(Figure 2C). These findings in mice are in agreement with our
studies in primary neurons demonstrating increased accumula-
tion of acetylation-resistant mutant Htt.
Acetylation at Lys444 Is Required for Neuroprotection
from Mutant Htt Toxicity in Primary Neurons
and Transgenic C. elegans Model of HD
To further establish that acetylation at K444 affects neuronal
toxicity, we found that primary neurons transduced with acetyla-
tion-resistant mutant Htt (lenti-Htt571-72Q-KR) showed signifi-
cantly higher toxicity compared to acetylated (lenti-Htt571-
72Q) mutant protein (Figure 3A). Based on these results, we
hypothesized that increased acetylation of mutant Htt at K444
by CBP may lead to neuroprotection. Previous studies demon-
strated that depletion of CBP enhanced toxicity whereas overex-
pression of CBP suppressed toxicity by mutant Htt (Bates et al.
2006; Nucifora et al., 2001). As expected from the previous work,
transfection of CBP significantly reduced Htt590-97Q-induced
cell death (Figure 3B). In contrast, neuronal toxicity mediatedby the acetylation-resistant mutant Htt (Htt590-97Q-KR) was
not protected by CBP (Figure 3B), suggesting that intact lysine
at position 444 is required for the CBP-mediated rescue.
To examine whether acetylation of mutant Htt can be neuro-
protective in vivo, we studied the effects of Htt acetylation in
C. elegans, a well-established model organism for polyglutamine
toxicity (Faber et al., 1999; Voisine and Hart, 2004). Recent work
showed that CBP protects neurons from mutant Htt toxicity in
the C. elegans model (Bates et al., 2006). Transgenic C. elegans
lines expressing CBP-HAT together with the N-terminal 564
amino acids of human Htt with intact K444 (Htt564-150Q) or
mutated K444 (Htt564-150Q-KR) were generated (Figure S4).
The transgenes were coexpressed with GFP in a subset of
neurons including the ASH sensory neurons. Consistent with
previous studies, the expanded Htt polyglutamine tract caused
neuronal degeneration and cell death (Faber et al., 1999). Degen-
eration is revealed as process retraction, which prevents uptake
of the fluorescent dye DiD from the environment via the exposed
sensory endings of ASH neurons, and polyglutamine-mediatedCell 137, 60–72, April 3, 2009 ª2009 Elsevier Inc. 63
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Figure 3. Acetylation of Mutant Htt at K444
Leads to Neuroprotection
(A) Lentiviral expression of acetylation-resistant Htt
(lenti-Htt571-72Q-KR) in primary cortico-striatal
cultures leads to increased toxicity compared to
acetylated Htt (lenti-Htt571-72Q), as determined
by caspase 3/7 activation. At least three indepen-
dent experiments were performed; *p < 0.01.
(B) Protection from Htt toxicity by CBP requires
acetylation of Htt at K444. Rat primary cortico-
striatal neurons were transfected with Htt590-
97Q or Htt590-97Q-KR together with CBP-HAT or
vector, and toxicity scored for at least 150 neurons
per sample. Results of three independent experi-
ments are expressed as means + SEM (p = 0.001).
(C) Acetylation of mutant Htt is protective in vivo in
C. elegans. In animals expressing acetylated
mutant Htt (Htt564-150Q) and CBP-HAT, the intact
GFP-expressing ASH neuron (arrow, left upper
panel) takes up the red fluorescent dye DiD (left
middle and lower panels); no degeneration is de-
tected. In contrast, in most animals expressing
acetylation-resistant mutant Htt (Htt564-150Q-KR)
and CBP-HAT, ASH neurons are GFP positive
(arrow, right upper panel) and DiD negative (right
middle and lower panels); neurodegeneration
increases with K444R mutation. Consistent with
previous studies, the ASI neurons (arrowheads)
express less Htt protein, are less consistently
affected by polyglutamine toxicity, and, hence,
were not scored.
(D) Affected ASH neurons were scored and
compared for Htt564-150Q + CBP and Htt564-
150Q-KR + CBP. Average percentage degener-
ated ± SEM is shown for multiple independent
strains (p = 0.0012, see Experimental Procedures
for details).cell death is assessed using GFP expression (Hart et al., 1999).
Intact ASH neurons express GFP and are DiD positive
(Figure 3C). Degenerating ASH neurons fail to take up DiD and
are detected as GFP-positive, DiD-negative cells (Figure 3C).
ASH neurons that have undergone cell death are both GFP
and DiD negative. While mutant Htt resulted in degeneration of
58% of neurons in the absence of CBP (not shown), coexpres-
sion of CBP was neuroprotective with only 14% of neurons
affected (Figure 3D). Importantly, when CBP was expressed
along with the acetylation-resistant mutant Htt (Htt564-150Q-
KR), almost 60% of the ASH neurons degenerated (Figure 3D),
suggesting that CBP-mediated neuroprotection in C. elegans
requires intact K444. These results are consistent with the data
obtained in primary neurons (Figure 3B) and provide further
in vivo evidence that acetylation of mutant Htt at K444 is required
for neuroprotection from mutant Htt toxicity.
Increased Acetylation at Lys444 Facilitates Clearance
of Mutant Huntingtin
Since the above experiments demonstrated increased accumu-
lation of acetylation-resistant mutant Htt, we directly investi-
gated whether stability of Htt protein is modulated by acetylation
of K444. Neuro2a cells were transfected with mutant or wild-type
Htt, treated with the protein synthesis inhibitor cycloheximide
(CHX), then monitored for the clearance of Htt. Previous studies64 Cell 137, 60–72, April 3, 2009 ª2009 Elsevier Inc.have suggested that lysosomal protein clearance may be
impaired by CHX treatment (Lawrence and Brown, 1993);
however, we provide evidence that lysosomal protein degrada-
tion remains intact in our experimental system (Figure S5).
Although wild-type Htt (Htt590-25Q) showed rapid clearance,
mutant Htt (Htt590-97Q) clearance was significantly slower at
baseline (Figure 4A). Cotransfection with CBP-HAT, but not
with mutant CBP with inactive HAT activity (CBP-HAT-DY),
significantly enhanced the clearance of mutant Htt (Figure 4B),
further suggesting that increased acetylation of mutant Htt
promotes its clearance. Importantly, no cellular toxicity was
observed in these experiments, which enabled the assessment
of protein clearance in the absence of cell death (Figure S6).
While cotransfection of CBP-HAT led to progressive clearance
of Htt590-97Q, the level of Htt590-97Q-KR remained compara-
tively unaltered (Figure 4C), further implicating K444 as the
required residue that modulates the stability of Htt protein.
Having demonstrated that CBP overexpression leads to
increased acetylation and clearance of mutant Htt, we then
examined the effects of HDAC1 knockdown on Htt clearance.
These experiments revealed that knockdown of endogenous
HDAC1 by shRNA significantly increased acetylation of mutant
Htt (Figure S7A) and enhanced its clearance, as determined by ra-
diolabeled pulse-chase. In contrast, mutagenesis of K444 to R
(K444R) led to a significant decrease of this clearance (Figure 4D).
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Figure 4. Acetylation of K444 Promotes Clearance of Mutant Htt
Neuro2a cells were transfected with Htt and CBP-HAT, treated with cycloheximide (CHX), and harvested at the indicated time points. Western blots were
analyzed by densitometry and values normalized to the amount of Htt at the time of cycloheximide treatment (100%). Values represent means of at least four
independent experiments + SEM; *p < 0.05; **p < 0.01 compared to Htt590-25Q (A), Htt590-97Q + CBP-HAT (B), and Htt590-97Q + CBP-HAT (C), respectively.
(A) Mutant Htt590-97Q has a longer half-life than wild-type Htt590-25Q.
(B) Cotransfection of CBP-HAT, but not the HAT-deficient CBP-HAT-DY, resulted in increased clearance of mutant Htt.
(C) Acetylation-induced clearance of mutant Htt depends on K444. Coexpression of CBP-HAT led to increased clearance of Htt590-97Q, whereas mutation of Htt
K444 to R prevented this effect of CBP-HAT.
(D) Enhanced clearance of Htt590-97Q by HDAC1 knockdown requires residue K444. Efficient knockdown of HDAC1 was achieved 3 days after transfection of
pSUPER-HDAC1 compared to transfection of pSUPER-luciferase in Neuro2a cells. b-tubulin was used as loading control (inset). Levels of Htt590-97Q were
monitored by radiolabeled pulse-chase. Knockdown of HDAC1 led to significant clearance of Htt590-97Q (32.6% ± 4.9%), comparable to levels achieved
with coexpression of CBP-HAT (20.0% ± 16.9%). Mutagenesis of K444 to R (K444R) led to a significant decrease of this clearance (73.0% ± 8.5%). Densitometry
measurements are expressed as % of signal after a 1 hr chase. Three independent experiments were performed and are represented as mean + SEM. *p < 0.001compared to Htt97Q+shHDAC1.No effect was observed with a shRNA construct targeting lucif-
erase (Figure S7B). Taken together, these results demonstrate
that modulation of Htt acetylation at K444 by CBP overexpression
or HDAC1 knockdown facilitates clearance of the mutant protein.
Clearance of Acetylated Mutant Huntingtin
by Autophagic-Lysosomal Pathway
To examine whether the lysosomal or the proteasomal pathway
is responsible for clearance of acetylated Htt, Neuro2a cells were
transfected with mutant Htt and treated with inhibitors of protea-
some or lysosome. While the proteasome inhibitors epoxomicin
and ALLN did not impede the clearance of mutant Htt
(Figure S8A), treatment of Neuro2A cells with the lysosomal
cathepsin L inhibitor leupeptin, cathepsin B, H, and L inhibitor
E-64d, lysosomal proton pump inhibitor bafilomycin A1 (Baf A1),
and the macroautophagy inhibitor 3-MA led to accumulation ofacetylated mutant Htt (Figures 5C and S8B), suggesting that
autophagy and lysosomal degradation play an important role in
its clearance. To further examine the contribution of autophagy
to acetyl-Htt clearance, we transfected mutant Htt into wild-
type mouse embryo fibroblasts (MEFs) and Atg5-deficient
MEFs (Atg5 KO) that exhibited defective autophagosome forma-
tion (Hara et al., 2006). When compared with the CBP-HAT-
transfected wild-type MEFs, clearance of mutant Htt was greatly
diminished in Atg5 KO MEFs transfected with CBP-HAT
(Figure S8C), confirming that autophagy represents the key
pathway for clearance of acetylated mutant Htt.
Next, we examined clearance of acetylated mutant Htt by
monitoring autophagic activity in live cells by LC3, a mammalian
homolog of yeast Atg8 that gets incorporated into autophagoso-
mal (AV) membrane (Kabeya et al., 2000; Tanida et al., 2005). LC3,
when fused to fluorescent proteins, can thus be used to monitorCell 137, 60–72, April 3, 2009 ª2009 Elsevier Inc. 65
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Figure 5. Acetylation of Mutant Htt Enhances Its Clearance by Autophagy
(A) Acetylation of mutant Htt at lysine 444 leads to increased recruitment of LC3 to autophagic vacuoles. RFP-Htt480-68Q and RFP-Htt480-68Q-KR were
transfected into COS-7 cells together with GFP-LC3 and CFP-CBP-HAT. Live cells were sequentially scanned to detect distribution of Htt (red), LC3 (green),
and CBP-HAT (blue). Scale bar, 10 mm. (a) Coexpression of RFP-Htt480-68Q with LC3 and CBP-HAT led to accumulation of LC3 puncta. (b) Cells transfected
with RFP-Htt480-68Q-KR, LC3, and CBP-HAT displayed a marked decrease in the LC3 puncta. (c) LC3-G120A mutant does not form punctate structure. (d) The
percentage of cells containing >5 puncta was scored in 150 cells per experiment. Values are expressed as means + SEM of three independent experiments.
(B) HeLa cell line, stably expressing YFP-LC3, was transfected with Htt590-97Q or Htt590-97Q-KR plus CFP-CBP-HAT or inactive CBP-HAT-DY. ANOVA anal-
ysis of the percentage of transfected cells with Htt puncta that colocalized with LC3 puncta revealed a significant effect of the presence of CBP-HAT (p < 0.001)
and the requirement of K444 (p < 0.001).
(C) Accumulation of mutant acetyl-Htt after treatment with lysosomal inhibitor leupeptin (200 mM). b-tubulin was used as loading control; p < 0.001.
(D) Clearance of acetylated mutant Htt is impeded by inhibition of lysosomal enzymes. Levels of Htt590-97Q, monitored by radiolabeled pulse-chase, were deter-
mined after 1, 8, 16, and 24 hr by immunoprecipitation for Htt590-97Q using an N-terminal FLAG antibody. Coexpression of CBP-HAT significantly enhanced
clearance of Htt590-97Q (filled square) compared to inactive CBP-HAT-DY (open square) (p < 0.05). This clearance required K444 (open diamond) (p <
0.005) and was impeded by 200 mM leupeptin (filled diamond) (p < 0.05). Significant degradation was achieved after a chase period of 16 hr and 24 hr (*p <
0.001). Densitometry measurements are expressed as % of signal after a 1 hr chase. Representative radiograms are shown. Three independent experiments
were performed and are represented as mean + SEM. ANOVA reveals a significant difference across chase time (F(3,23) = 61.779, p < 0.0001), across group
(F(3,23) = 19.656, p < 0.0001), and across an interaction between chase time and group (F(9,23) = 5.479, p = 0.005).
(E) Acetyl-Htt is preferentially localized to the cytoplasm. Levels of cytoplasmic and nuclear acetyl-Htt and CBP-HAT were determined by subcellular fractionation
and western blotting. HDAC1 and b-tubulin were used as nuclear and cytoplasmic markers, respectively. Results are representative of three independent exper-
iments.the formation of AV in live cells by the appearance of LC3-positive
puncta (Mizushima, 2004). We found that COS-7 cells expressing
Htt480-68Q displayed significantly more LC3-positive vacuoles
compared to cells expressing Htt480-68Q-KR (Figures 5A,
S9A, and S9B). Transfections of LC3 mutant, GFP-LC3-G120A,
that does not get incorporated into AV membranes (Kabeya66 Cell 137, 60–72, April 3, 2009 ª2009 Elsevier Inc.et al., 2000) led to a dramatic decrease in the number of LC3
puncta (Figure 5A), suggesting that the observed LC3 puncta
represent AV rather than nonspecific GFP-LC3 aggregates.
To quantify the frequency with which Htt-positive puncta colo-
calized with LC3-positive puncta, Htt590-97Q or Htt590-97Q-
KR mutant Htt was cotransfected together with CBP-HAT into
HeLa cells that stably express YFP-tagged LC3. The number of
Htt-containing puncta per cell and the percentage of transfected
cells exhibiting this colocalization event were determined
(Figure 5B). Correlative with the increased degradation of acety-
lated mutant Htt, there was a significantly higher probability of
finding Htt puncta colocalizing with LC3 in cells transfected
with acetylated Htt (Figure 5B). In contrast, mutating the lysine
444 to an arginine eliminated the ability of CBP-HAT to augment
the colocalization of LC3 and Htt (Figure 5B), suggesting prefer-
ential targeting of acetylated mutant Htt to autophagosomes.
Next, we sought to directly investigate whether targeting of
acetylated Htt to autophagosomes results in increased clearance
of the mutant protein. Similar to our observation using CHX, coex-
pression of CBP-HAT but not inactive CBP-HAT-DY led to
significantly enhanced clearance of Htt590-97Q (Figure 5D) as
determined by radiolabeled pulse-chase experiments. This
clearance required K444 (>, Figure 5D) and was indeed impeded
by lysosomal inhibitor leupeptin (A, Figure 5D), further suggest-
ing that acetylation of Htt at K444 promotes autophagic and
lysosomal degradation of the mutant protein.
CBP is a resident nuclear protein that is known to acetylate
histone proteins (Bannister and Kouzarides, 1996). Since CBP
presumably acetylates Htt in the nucleus and clearance by au-
tophagy takes place in the cytoplasm, we examined if acetylated
Htt is indeed in the correct cellular compartment to be a substrate
for autophagy. While CBP was primarily localized to the nucleus,
acetylated Htt was predominantly found in the cytoplasmic
compartment (Figure 5E), suggesting that, upon acetylation by
CBP in the nucleus, mutant Htt becomes available for autopha-
gic degradation in the cytoplasm.
Acetylated Mutant Huntingtin Is Preferentially
Trafficked into Autophagosomes
To directly examine whether acetylated mutant huntingtin can be
targeted to autophagosomes, the distribution of mutant Htt
(Htt590-97Q) was examined in autophagosomes isolated from
Neuro2a cells by modified versions of two previously published
protocols (Marzella et al., 1982; Stromhaug et al., 1998). Neuro2a
cells were cotransfected with acetylated (Htt590-97Q) or acety-
lation-resistant (Htt590-97Q-KR) mutant Htt and CBP-HAT and
autophagosomes isolated in the absence of chemical modifiers
of autophagosomal maturation. Cryo-electron micoscopy (cryo-
EM) of gradient flotation autophagosomal fractions revealed
a variety of membranous structures consistent with previous
publications (Reggiori and Klionsky, 2002). These fractions
were enriched in multivesicular bodies that are morphologically
consistent with autophagosomes, large multivesicular endo-
somes and/or autolysosomes and unilamellar structures like
transport vesicles (Figure 6A). Immuno-EM using an antibody
against LC3 revealed that only the multilamellar structures
were positive for LC3 (Figure 6B). Autophagosome-enriched
fractions (AV) were also confirmed by probing for the
membrane-bound form of LC3, LC3-II (Figures 6C and S10).
Whereas both acetylated and acetylation-resistant mutant Htt
were detected at similar levels in the cytosolic fraction, acety-
lated Htt was preferentially detected in the AV fraction
(Figure 6C). To determine if the acetylated Htt detected in the
AV fraction is indeed within a membranous structure, a proteaseprotection assay was performed. In the cytosolic fraction, both
Htt590-97Q and the non-membrane-bound form of LC3 (LC3-I)
were mostly degraded after exposure to 1 mg/ml proteinase K.
In contrast, despite degradation of LC3-I at 1 mg/ml proteinase
K in the AV fraction, Htt590-97Q did not degrade until 25 mg/ml
proteinase K when the membrane-bound form of LC3 (LC3-II)
was also degraded (Figure 6D). Taken together, these results
further suggest that acetylation at K444 facilitates trafficking of
the mutant protein into autophagosomes for degradation.
p62-Dependent Clearance of Acetylated Mutant
Huntingtin
In order to further examine mechanisms of clearance of acetylated
mutant Htt, we evaluated the biochemical state of Htt upon acety-
lation. Extracts from Htt480-68Q/CBP-HAT cotransfected Neu-
ro2a cells were analyzed by native size-exclusion chromatography
(SEC) followed by western blot analysis of collected fractions.
Although the expected molecular mass of the monomeric
Htt480-68Q is 59 kDa, the majority of acetylated Htt eluted off as
a high molecular weight (HMW) species corresponding to
2000–294 kDa in size (Figure 7A). Further analysis of this fraction
by denaturing SDS-PAGE revealed that the HMW species con-
tained a 69 kDa Ac-Htt species (Figure 7A). Treatment of cells
with the lysosomal inhibitor Baf A1 enhanced the amount of
HMWAc-Httspecies,whereasno change in the53 kDamonomeric
Ac-Htt species was observed (HMW/monomer ratios: DMSO = 16;
Baf A1 = 45) (Figure 7A). These results suggest that acetylation of
mutant Htt at K444 leads to formation of a larger complex of
proteins that may serve as a substrate for lysosomal degradation.
Next, we examined the role of p62/SQSTM1 (also called se-
questosome 1) that interacts with LC3 and has been suggested
to have a role in autophagic clearance of protein aggregates
(Komatsu et al., 2007). Recent data suggest that reduction of
p62 protein levels or interference with p62 function significantly
increases mutant Htt-mediated cell death (Bjorkoy et al., 2005).
To determine if p62 plays a role in the clearance of Ac-Htt, we
used the HN10 neuronal cell line (Weiss et al., 2009) to generate
conditional expression of a 573 aa fragment of mutant Htt
(573-72Q). Initial characterization of this cell line revealed
a half-life of mutant Htt of about 25 hr (Figure S11). Consistent
with our findings in CHX-based experiments (Figure 4A), the
half-life of the wild-type (WT) Htt (573-25Q) in HN10 cells was
significantly shorter (12.5 hr) compared to the mutant protein
(data not shown). As expected, we observed a significant
decrease in half-life of Htt573-72Q upon CBP-mediated acetyla-
tion, compared to vector- or CBP-DY-transfected cells (Fig-
ure 7C). Interestingly, knockdown of endogenous p62 in HN10
cells by approximately 40% significantly hindered the clearance
of Ac-Htt (Figures 7B and 7C). Moreover, p62 preferentially inter-
acts with Ac-Htt (Figure S13), further suggesting that p62 plays
a role in clearance of acetylated mutant Htt.
DISCUSSION
We demonstrate that in tissue culture models of HD as well as in
mouse and human HD brain, there is baseline acetylation of
mutant Htt at K444. Acetylation of mutant Htt at this residue
can be increased by CBP-mediated acetylation or the inhibitionCell 137, 60–72, April 3, 2009 ª2009 Elsevier Inc. 67
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Figure 6. Acetylated Mutant Htt Is Trafficked to Autophagosomes
(A) Purification of autophagosomes (AV). Neuro2A cells were fractionated and AV, lysosomes, and endoplasmic reticulum (ER) isolated using two distinct proto-
cols, as described in Experimental Procedures. Cryo-EM revealed fractions enriched in multivesicular bodies that are morphologically consistent with AV (1, 2)
and unilamellar structures like transport vesicles (3).
(B) To determine whether LC3 was associated with membrane structures, AV fractions were incubated with an antibody against LC3 followed by iron-rich
magnetic beads conjugated to Protein A. (i) Beads imaged alone. (ii) Unilamellar transport vesicles were not labeled by beads. (iii and iv) Multilamellar autopha-
gosomal-like particles are labeled by beads.
(C) Preferential trafficking of acetylated Htt to autophagosomes. Cells were fractionated and AV isolated, run on SDS-PAGE, and probed with anti-Htt antibody or
LC3 antibody. Htt590-97Q was preferentially detected in the AV-enriched fractions compared to Htt590-97QKR. The cytosolic fractions predominantly contain
the unbound form of LC3 (LC3-I), while the AV-enriched fractions contain the membrane-bound form of LC3 (LC3-II). Fraction ‘‘AV/ER’’ differs from ‘‘AV’’ as it is
also enriched for ER markers such as calnexin (not shown). Std, protein standard.
(D) Mutant Htt is detected within the AV membrane fraction. Protease protection assay was performed with 20 mg of protein from a cytosol fraction or AV fraction
collected from (C), subjected to increasing amounts of proteinase K (PK) and examined by SDS-PAGE. In the cytosolic fraction, both Htt590-97Q and the LC3-I
were degraded after exposure to 1mg/ml PK. In the AV fraction, Htt590-97Q did not degrade until 25mg/ml PK when the LC3-II was also degraded. Htt590-97Q was
detected using MAB5492 (Chemicon) and LC3 with rabbit polyclonal antibody (Abcam). A representative image from three independent experiments is shown.of HDAC1, which in turn leads to an increased clearance of
mutant Htt and neuroprotection in vitro and in vivo. Previous
studies showed that full-length and truncated Htt are found in
the nucleus where Htt can interact with the transcriptional
machinery to disrupt gene expression (Kegel et al., 2002; Dunah
et al., 2002; Zhai et al., 2005; Cui et al., 2006). Our results suggest
that as mutant Htt accumulates in the nucleus, it can become
acetylated by CBP and then exported to the cytoplasm for auto-
phagic degradation. Our finding of increased clearance of acet-
ylated mutant Htt is in agreement with the observation that acet-
ylation-resistant mutant Htt dramatically accumulates and
causes neurodegeneration in cultured neurons and in mouse
brains (Figures 2 and 3). Interestingly, we detect baseline acety-
lation of only mutant but not wild-type Htt in both cultured cells
and mouse or human HD brain. Since we observe relatively rapid
clearance of wild-type Htt under baseline conditions when
compared to the mutant protein, wild-type protein may also be68 Cell 137, 60–72, April 3, 2009 ª2009 Elsevier Inc.acetylated but degraded too rapidly to permit detection. The
accumulation of mutant Htt in HD patients, despite acetylation,
is clearly an indication that even this attempt by the neuron is
not sufficient to evade disease onset; however since our data
in mice and cultured neurons indicate that the acetylation-resis-
tant form of mutant Htt accumulates even more, it can be
concluded that some benefit arises from baseline acetylation.
Moreover, our data suggest that by increasing the rate of acety-
lation at K444, we can enhance degradation of mutant huntingtin
that results in neuroprotection, suggesting that acetylation of
K444 represents a means of regulated clearance of mutant Htt.
From a standpoint of therapy for human HD, a specific decrease
in mutant but not wild-type Htt would be expected to delay
disease onset and progression (Yamamoto et al., 2000; Arrasate
et al. 2004; Graham et al., 2006b). While CBP and the existing
HDAC inhibitors are not sufficiently specific as therapeutic
agents, we describe a pathway that should allow for
Figure 7. p62-Mediated Clearance of Mutant Htt
(A) Acetyl-Htt exists as a HMW species and accumulates upon lysosomal inhibition. Neuro2a cells were cotransfected with Htt480-68Q and CBP-HAT, in the
presence of bafilomycin A1 (Baf A1, 100 nM) or DMSO. Triton-soluble lysates were analyzed by size-exclusion chromatography (SEC) and western blot using
the anti-acetyl K444 antibody (bottom). Neuron-specific enolase (NSE) was used to monitor gel filtration column performance and loading. The horizontal
MW marker (kDa) represents the MW obtained by SEC analysis as determined by the elution of globular protein standards. The vertical marker (kDa) represents
the MW obtained by SDS-PAGE analysis of fractions. Western blots shown were analyzed by densitometric analysis from at least three independent experiments
and normalized to NSE (top). Inset, the amount of monomeric Ac-Htt is shown at a smaller y axis.
(B) Knockdown of p62 in inducible HN10 cell lines expressing Htt573-72Q. Values are the mean ± SEM (n = 5); *p = 0.01 for p62 shRNA compared to control (Ctrl)
shRNA, normalized to a-tubulin.
(C) Clearance of Ac-Htt is mediated by p62 in HN10 cells. Mutant Htt half-life was determined in untransfected (Un) or cells transfected with empty vector (Vect),
CBP D-Y, CBP-HAT, control shRNA, or p62 shRNA. Half-life values of Htt573-72Q were determined as described in Experimental Procedures. The values repre-
sent the mean ± SEM (n = 5). *p < 0.01 compared to Un and Vect; *p < 0.05 compared to CBP D-Y; **p < 0.01 compared to Ctrl-shRNA.development of more selective compounds to specifically
promote acetylation and clearance of mutant Htt in HD.
We find that acetylation of mutant Htt at K444 promotes clear-
ance of the mutant protein via an autophagic-lysosomal
pathway. Recent work has revealed an important role for
autophagy in general control of protein turnover in the central
nervous system (Hara et al., 2006; Komatsu et al., 2006). In
HD, autophagy is also emerging as an important cellular defense
mechanism (Kegel et al., 2000; Ravikumar et al., 2004;
Yamamoto et al., 2006). In these previous studies, shorter Htt
fragments that rapidly aggregate were studied. Unlike the short
fragments, the longer Htt fragments used in our study did not
form visible aggregates, a phenomenon often seen with longer
fragments of Htt (Hackam et al., 1998; Lunkes and Mandel,
1998; Menalled et al., 2003). We showed the enrichment of acet-ylated, but not acetylation-resistant, 590 aa Htt fragment in puri-
fied autophagosomes, further suggesting that these longer Htt
fragments can be trafficked to autophagosomes. Biochemical
analysis indicated that acetyl-Htt is present mainly as a HMW
species, with <10% in the monomeric form. The inherent pro-
perty of polyQ-containing proteins to self-aggregate has been
well established (Perutz, 1999; Scherzinger et al., 1997), sug-
gesting that Ac-Htt detected in the HMW fractions may exist,
in part, as a self-associated oligomeric species. Lysosomal inhi-
bition caused a specific accumulation of HMW Ac-Htt, whereas
the monomeric form was unchanged suggesting that a soluble
oligomeric Ac-Htt is likely the substrate for autophagic degrada-
tion. This is further supported by the fact that accelerated clear-
ance of Ac-Htt is affected by levels of p62, a protein known to co-
localize to mutant huntingtin inclusions (Nagaoka et al., 2004),Cell 137, 60–72, April 3, 2009 ª2009 Elsevier Inc. 69
Published: April 2, 2009and has been previously implicated in modulating levels of
mutant exon1-Htt (Bjorkoy et al., 2005). While our results
suggest that the HMW species of acetylated Htt may serve as
a substrate for p62-mediated degradation of mutant Htt, further
studies will be required to elucidate the precise nature of the
interaction between p62 and acetylated Htt.
Importantly, current approaches to modulate autophagy inhibit
mTOR (i.e., rapamycin) and in turn result in a global and nonspe-
cific activation of autophagy and other cellular pathways that
could have deleterious consequences in neurons (Levine and
Kroemer, 2008). Our study showed that a direct modification of
a target protein promotes its specific clearance and provides
a link between protein acetylation and targeted degradation by
autophagy. Since acetylation of nonhistone proteins has only
recently emerged as an important cellular mechanism (Kouzar-
ides, 2000), it will be of interest to further examine whether protein
acetylation represents a more general regulatory mechanism for
selective targeting of proteins for lysosomal degradation.
EXPERIMENTAL PROCEDURES
Cell Culture, Live-Cell Imaging, Lentiviral Transductions
Neuro2a, COS-7, HeLa, MEFs, and primary neurons were transfected using
Lipofectamine 2000. Toxicity was measured using a ToxiLight nondestructive
cytotoxicity bioassay kit (Cambrex) according to the manufacturer’s protocol.
For primary cultures, cortical neurons were isolated from Sprague-Dawley rats
at E19. Cell death was monitored as described previously (Cui et al., 2006). For
live-cell imaging COS-7 were analyzed on a Zeiss LSM 510 confocal micro-
scope (Carl Zeiss, Jena, Germany). Cells were kept at 37C and 5% CO2 on
the microscope stage and images were acquired sequentially in red, green,
and blue channels. To create YFP-LC3 stable cell lines, Tet-off HeLa cell lines
were cotransfected with YFP-LC3 and pTk-Hygro (10:1) with Lipofectamine
(Invitrogen) per manufacturer’s instructions. For studies of Htt half-life, HN10
cells were stably transfected with a 573-72Qaa fragment of Htt using the
Rheoswitch-inducible expression system (New England Biolabs, Ipswich,
MA, USA) and expression induced with 500 nM Rheoswitch ligand (RSL1,
New England Biolabs). The first order rate constant (k) of Htt clearance curve
was obtained by an exponential decay fit, and protein half-life was determined
by the equation Htt t1/2 = ln(2)/k. Rat embryonic primary cortico-striatal
neurons were infected with lentiviral vectors on DIV2. For the in vivo experi-
ments, concentrated lentiviral stocks expressing Htt571-72Q or Htt571-
72Q-KR were injected in the left or the right striatum of pentobarbital anesthe-
tized C57BL/6 mice using stereotaxic coordinates of 0.4 mm rostral to bregma,
1.8 mm lateral to midline, and 3.5 mm ventral from the dural surface. The brain
was perfused and processed as described (Cui et al., 2006).
Mass Spectrometry
Htt480-68Q was immunoprecipitated with Htt antibody (MAB5492) from trans-
fected COS-7 cells treated with TSA (1 mM) and NAM (5 mM). Protein bands
were stained with SimplyBlue Safe Stain (Invitrogen), digested with trypsin,
and analyzed by mass spectrometry (LC-MS/MS). MS/MS data were analyzed
by the SEQUEST algorithm. MS was performed at Taplin Biological Mass
Spectrometry Facility (Thermo Electron 7-T LTQ FT), Partners HealthCare
Center for Genetics and Genomics Proteomic Facility (ThermoFinnigan
DECA LCQ), and the LNT/NIMH/NIH (Finnigan LCQ Classic).
Purification of Autophagosomes and Electron Microscopy
To collect the lysosomal/AV fraction supernatants, Neuro2a cells were frac-
tionated using a discontinuous Nycodenz (Stromhaug et al., 1998) or 50%
metrizamide gradient (Marzella et al., 1982). AV-enriched fractions from both
methods were collected and examined by electron cryo-microscopy and by
immunoblotting. For immunolabeling of vesicles, anti-LC3 antibody (Nano-
tools, Germany) was incubated at 1:250 with AV fractions. For cryo-EM, organ-
elles were imaged in vitreous ice over open holes on a perforated carbon70 Cell 137, 60–72, April 3, 2009 ª2009 Elsevier Inc.support to preserve all details in the image. Samples were imaged on a Tecnai
20 FEG electron microscope operating at 200 kV, with magnifications from
25,000 to 50,000 and a typical defocus of 3.5 mm. For protease protection,
20 mg of protein from the cytosolic or AV fraction generated from the Marzella
protocol were subject to 0, 0.2, 1, 5, or 25 mg/ml of proteinase K.
Radiolabeled Pulse-Chase Experiments
Radioactive isotope was purchased from ICN Pharmaceuticals. Neuro2a cells
were transfected using Lipofectamine 2000 per manufacturer’s instructions.
GFP-CBP-HAT was transfected in a 1:8 ratio with Htt590 constructs, and
pSUPER-HDAC1 or pSUPER-Luciferase were transfected in 1:1 ratio with
Htt590 constructs. Cells were incubated in serum-free, methionine-free
DMEM, followed by a 3 hr pulse with [35S]methionine/cysteine (0.03 mCi/ml).
C. elegans Assays
Transgenic animals were generated by injecting pqe-1(rt13) unc-32(e189) pha-
1(e2123) animals with osm-10::GFP (pHA#29, 40 ng/ml), osm-10::CBP-HAT
(CBP-HAT, 10 ng/ml), and osm-10::Htn564-150Q with or without the K444R
mutation (100 ng/ml). pJM#67 (elt-2::GFP) was used as a selection marker.
ASH neuron degeneration was assessed in aged animals using GFP expres-
sion and DiD staining as described previously (Bates et al., 2006). No differ-
ence was observed in ASH neuronal degeneration and death in pqe-
1;HtnQ150 animals with (7% degenerated and 89% dead) or without (5%
degenerated and 94% dead) the unc-32(e189) mutation (Figure S4).
Size-Exclusion Chromatography
Neuro2a cells were transiently cotransfected with Htt 480-68Q and CBP-HAT,
treated with either 100 nM Baf A1 (Calbiochem) or DMSO, and lysate resolved
on a Superdex 200 HR10/30 column (GE Healthcare BioSciences, Uppsala,
Sweden) as described previously (Mazzulli et al., 2006). The column was cali-
brated using a mixture of globular proteins (HMW standards, GE Healthcare
BioSciences) and the void volume determined by the elution of blue dextran
(2000 kDa). Normalized Ac-Htt signal was graphed according to elution
volume of globular protein standards, and chromatographic peaks were
integrated using GraphPad Prism software, V4 (GraphPad Software, Inc.
LaJolla, CA, USA). Integrated peak values were used to calculate oligomer
(pk at 1280 kDa)/monomer (pk at 53 kDa) ratios.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and thir-
teen figures and can be found with this article online at http://www.cell.com/
supplemental/S0092-8674(09)00317-1.
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